217 related articles for article (PubMed ID: 30526346)
1. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
Hatakeyama Y; Ohnishi H; Suda K; Okamura K; Shimada T; Yoshimura S
J Oncol Pharm Pract; 2019 Dec; 25(8):2023-2026. PubMed ID: 30526346
[TBL] [Abstract][Full Text] [Related]
2. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
4. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
6. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.
Sakaguchi C; Ashida K; Yano S; Ohe K; Wada N; Hasuzawa N; Matsuda Y; Sakamoto S; Sakamoto R; Uchi H; Furue M; Nomura M; Ogawa Y
Curr Oncol; 2019 Feb; 26(1):e115-e118. PubMed ID: 30853818
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
[TBL] [Abstract][Full Text] [Related]
8. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
Miyauchi M; Toyoda M; Zhang J; Hamada N; Yamawaki T; Tanaka J; Harada K; Kashizaki F; Fukagawa M
J Diabetes Investig; 2020 May; 11(3):748-749. PubMed ID: 31587459
[TBL] [Abstract][Full Text] [Related]
10. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
Harsch IA; Konturek PC
Wiad Lek; 2018; 71(5):945-948. PubMed ID: 30176620
[TBL] [Abstract][Full Text] [Related]
11. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
Mae S; Kuriyama A; Tachibana H
J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
13. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
Yamamoto N; Tsurutani Y; Katsuragawa S; Kubo H; Sunouchi T; Hirose R; Hoshino Y; Ichikawa M; Takiguchi T; Yukawa H; Arioka H; Saitou J; Nishikawa T
Intern Med; 2019 Oct; 58(19):2825-2830. PubMed ID: 31243198
[TBL] [Abstract][Full Text] [Related]
14. A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.
Jodai T; Yoshida C; Sato R; Kakiuchi Y; Sato N; Iyama S; Kimura T; Saruwatari K; Saeki S; Ichiyasu H; Fujii K; Tomita Y
Immun Inflamm Dis; 2019 Mar; 7(1):3-6. PubMed ID: 30461210
[TBL] [Abstract][Full Text] [Related]
15. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
Seo JH; Lim T; Ham A; Kim YA; Lee M
Medicine (Baltimore); 2022 Sep; 101(35):e30456. PubMed ID: 36107574
[TBL] [Abstract][Full Text] [Related]
16. Fulminant Type 1 Diabetes Mellitus Caused by Long-Term Nivolumab Administration Followed by Nivolumab plus Cabozantinib Combination.
Homma T; Yoshida N; Tanaka K; Isemura M; Torii S; Kinoshita T; Esaki H; Sakakibara T; Takimoto N
Chemotherapy; 2023; 68(1):44-47. PubMed ID: 36327909
[TBL] [Abstract][Full Text] [Related]
17. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.
Munakata W; Ohashi K; Yamauchi N; Tobinai K
Int J Hematol; 2017 Mar; 105(3):383-386. PubMed ID: 27696192
[TBL] [Abstract][Full Text] [Related]
18. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
19. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
[TBL] [Abstract][Full Text] [Related]
20. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
